Cullinan Oncology LLC Earnings
The next earnings date for Cullinan Oncology LLC has not yet been scheduled.
Analyst Estimates of Cullinan Oncology LLC Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Cullinan Oncology LLC Earnings: Historical
| 11/10/2026 | Before Market | $-0.74 | 6.33% |
| 08/06/2026 | Before Market | $-0.81 | -14.08% |
| 05/07/2026 | Before Market | $-0.75 | 10.71% |
| 03/05/2026 | --- | $-0.77 | 11.89% |
| 11/06/2025 | Before Market | $-0.77 | 13.48% |
| 08/07/2025 | Before Market | $-1.07 | -28.92% |
| 05/08/2025 | Before Market | $-0.74 | 8.64% |
| 03/12/2025 | Before Market | $-0.73 | 1.66% |
| 11/07/2024 | Before Market | $-0.69 | 10.39% |
| 08/08/2024 | Before Market | $-0.75 | -2.74% |
More About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
“Cullinan Oncology LLC Earnings” Can Refer to the Cullinan Oncology LLC Earnings Date
Some people say “Cullinan Oncology LLC earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Cullinan Oncology LLC position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Cullinan Oncology LLC Stock on the Earnings Date
If you own Cullinan Oncology LLC stock (CGEM) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Cullinan Oncology LLC might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Cullinan Oncology LLC shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Cullinan Oncology LLC Earnings
You can contact us any time if you would like to ask questions about Cullinan Oncology LLC earnings or anything else related to the stock market.